Difficulty: Medium
Average Score: 62%
Practice
Which of the following inhibitors binds only to the anionic site of the cholinesterase enzyme?
Correct answer
C
Rationale
The correct answer to the question is C) Edrophonium. Edrophonium is a reversible cholinesterase inhibitor that binds exclusively to the anionic site of the enzyme. This specificity allows edrophonium to competitively block the breakdown of acetylcholine, leading to increased cholinergic activity in the synaptic cleft.
Neostigmine (A) and Physostigmine (B) are cholinesterase inhibitors that bind both the anionic and esteratic sites of the enzyme, leading to a more prolonged inhibition of cholinesterase activity compared to edrophonium. Dyflos (D), on the other hand, binds irreversibly to the esteratic site of cholinesterase, resulting in long-lasting inhibition that is not easily reversed.
Understanding the specific binding properties of cholinesterase inhibitors is crucial in pharmacology as it impacts their mechanism of action, duration of effect, and potential side effects. By knowing the differences between these inhibitors, healthcare professionals can make informed decisions when selecting the most appropriate drug for a patient based on their individual needs and the desired pharmacological outcome.
Neostigmine (A) and Physostigmine (B) are cholinesterase inhibitors that bind both the anionic and esteratic sites of the enzyme, leading to a more prolonged inhibition of cholinesterase activity compared to edrophonium. Dyflos (D), on the other hand, binds irreversibly to the esteratic site of cholinesterase, resulting in long-lasting inhibition that is not easily reversed.
Understanding the specific binding properties of cholinesterase inhibitors is crucial in pharmacology as it impacts their mechanism of action, duration of effect, and potential side effects. By knowing the differences between these inhibitors, healthcare professionals can make informed decisions when selecting the most appropriate drug for a patient based on their individual needs and the desired pharmacological outcome.